Global Lung Cancer Therapeutics Market Forecast to 2025

  • 10
    Enquiry Hours

Cancer is a group of heterogenous disease affecting various anatomic locations of the body. The unusually growing cells move from the original site to other regions of the body via lymph and blood system. Lung cancer, also referred as lung carcinoma or pulmonary carcinoma is a malignant lung tumor that is characterized by uncontrolled cell growth in tissues of the lung. According to an estimation of the American Cancer Society, in 2019, the new lung cancer cases are estimated to be around 228,150 and deaths from lung cancer at 142,670 in the US. Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) are two main types of lung cancer. SCLC accounts for only 15% of all lung cancers cases but it is much more aggressive than NSCLC.

The global lung cancer therapeutics market is expected to grow at high growth rate due to alarming increase in lung cancer incidences globally propelled by growing awareness on the importance of early diagnosis of this deadly disease, advent and acceptance of cell-and gene-based immunotherapies, growing use of outcome-based reimbursement pricing by the leading payers, changing lifestyles, increasing tobacco consumption in form of chewing and smoking, rapid side effects of industrialization, and increasing geriatric population. However, high cost of therapies, competition from the generic drugs and biosimilars, and side effects of radiation and chemotherapies are some of the factors which are still restraining the growth of the overall global lung cancer therapeutics market.

This report provides detailed study and revenue opportunity of lung cancer therapeutics across various segments such as disease type, molecule type, and region. The global lung cancer therapeutics market by disease type is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). By molecule type, the global market is segmented into small molecules and biologics. By therapy, the global is segmented into chemotherapies, immunotherapies, and combinations as first, second, and third-line treatment along with neoadjuvant & adjuvant/adjunct options.

According to Infoholic Research, the “Global Lung Cancer Therapeutics” market is expected to grow at a CAGR over 10%* during the forecast period 2019–2025.

The report provides details about the adoption of lung cancer therapeutics across various regions including North America, Europe, Asia Pacific, and Rest of the World. The report also contains an in-depth analysis of vendor profiles, which includes financial health, business units, key business priorities, SWOT, strategies, and views of major players in the global lung cancer therapeutics market. The report also provides details on the impact of recent immunotherapy approvals on the forecasted market and the breakdown by upcoming therapies CART-T, new immune checkpoint inhibitors such as anti sLAG-3 (with the advent of anti PD-1 and anti PD-L1 therapies as successfully established and approved therapies in the market)

The study offers a comprehensive analysis of the “Global Lung Cancer Therapeutics Market”, providing key insights of the industry. Also, the report aims to provide an opportunity for players to understand the latest trends, current market scenarios, government initiatives, and competitive landscape. In addition, it helps the venture capitalists in understanding the companies better and take informed decisions.


Request for TOC at

Infoholic research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting

Infoholic Research Healthcare Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.